Correlation Between Cullinan Oncology and Puma Biotechnology
Can any of the company-specific risk be diversified away by investing in both Cullinan Oncology and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cullinan Oncology and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cullinan Oncology LLC and Puma Biotechnology, you can compare the effects of market volatilities on Cullinan Oncology and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cullinan Oncology with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cullinan Oncology and Puma Biotechnology.
Diversification Opportunities for Cullinan Oncology and Puma Biotechnology
-0.57 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Cullinan and Puma is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding Cullinan Oncology LLC and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and Cullinan Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cullinan Oncology LLC are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of Cullinan Oncology i.e., Cullinan Oncology and Puma Biotechnology go up and down completely randomly.
Pair Corralation between Cullinan Oncology and Puma Biotechnology
Given the investment horizon of 90 days Cullinan Oncology LLC is expected to under-perform the Puma Biotechnology. But the stock apears to be less risky and, when comparing its historical volatility, Cullinan Oncology LLC is 1.98 times less risky than Puma Biotechnology. The stock trades about -0.38 of its potential returns per unit of risk. The Puma Biotechnology is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest 321.00 in Puma Biotechnology on September 13, 2024 and sell it today you would lose (29.00) from holding Puma Biotechnology or give up 9.03% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Cullinan Oncology LLC vs. Puma Biotechnology
Performance |
| Timeline |
| Cullinan Oncology LLC |
| Puma Biotechnology |
Cullinan Oncology and Puma Biotechnology Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Cullinan Oncology and Puma Biotechnology
The main advantage of trading using opposite Cullinan Oncology and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cullinan Oncology position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.| Cullinan Oncology vs. Puma Biotechnology | Cullinan Oncology vs. Iovance Biotherapeutics | Cullinan Oncology vs. Sarepta Therapeutics | Cullinan Oncology vs. Day One Biopharmaceuticals |
| Puma Biotechnology vs. Ultragenyx | Puma Biotechnology vs. Crinetics Pharmaceuticals | Puma Biotechnology vs. Arvinas | Puma Biotechnology vs. Revolution Medicines |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Complementary Tools
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |